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analysis showed no relationship between cosmetic result and 
age (p>0.13). 
 
Conclusion: Our experiences is limited to a low number of 
cases but confirm that adjuvant radiotherapy is not 
controindicated when reconstructive surgery is expected. The 
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Purpose or Objective: To report 2-years toxicity and clinical 
results of hypofractionated simultaneous integrated boost 
(SIB) tecnique with Volumetric Modulated Arc Therapy 
(VMAT) as adjuvant treatment after breast-conserving 
surgery. 
 
Material and Methods: Patients presenting early-stage breast 
cancer were enrolled in a phase II trial. Eligibility criteria: 
age>18 years, invasive cancer or DCIS, Stage I-II (T<3 cm and 
N≤3), breast-conserving surgery without oncoplastic 
reconstruction, any systemic therapy was allowed in 
neoadjuvant or adjuvant setting. All patients underwent 
VMAT-SIB technique to irradiate the whole breast and the 
tumor bed. Doses to whole breast and surgical bed were 
40.5Gy and 48Gy, respectively, delivered in 15 fractions over 
3 weeks. Acute and late skin toxicities were recorded based 
on RTOG scoring criteria and CTCAE v. 4.0, respectively. 
Cosmetic outcome was assessed as excellent/good or 
fair/poor, according to the Harvard scale. 
 
Results: The present study focused on long-term results of a 
cohort of 144 patients with a minimum follow-up of 24 
months (median 37, range 24-55 months). Median age was 62 
y.o. (range 30-88). At one year, the highest reported skin 
toxicity was G1, in 14% of the patients; this data dropped to 
4% at the last follow-up, after more than 2 years. Breast pain 
was recorded in 21.6% of the patients 6 months after 
treatment, while it was present in 3.5% of the patients at the 
last follow-up, showing a significant improvement with time. 
No correlation with liponecrosis as recorded from ultrasound 
exam, nor with dosimetric data. Skin toxicity was correlated 
with breast volume. No pulmonary or cardiological toxicities 
were recorded. After an early evaluation of clinical 
outcomes, only one case presented disease relapse, as liver 
metastases. 
 
Conclusion: The hypofractionated VMAT-SIB course as 
adjuvant treatment after breast-conserving surgery showed 
to be safe and effective with optimal local control. This 
approach requires validation with long-term follow-up data. 
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Purpose or Objective: To investigate the impact of the boost 
dose escalation on ipsilateral breast tumor recurrence (IBTR), 
for breast cancer patients with involved surgical margins 
after breast conserving surgery. 
 
Material and Methods: Between January 1998 and December 
2010 at Asan Medical center, among 4275 breast cancer 
patients who were treated with breast conserving therapy 
(BCT), a total 192 patients were treated with boost dose over 
10 Gy for involved resection margin. We retrospectively 
analyzed the outcomes in 192 patients who had whole breast 
irradiation of 50.4 Gy followed by median boost dose 15.0 Gy 
(range, 12 - 16 Gy) for breast cancer with involved resection 
margin. Surgery preceded referral for radiotherapy with a 1-2 
mm margin of macroscopically normal tissue. The resection 
margins were evaluated by pathologist for the presence of 
invasive carcinoma or ductal carcinoma in situ at the inked 
margin. Neoadjuvant chemotherapy was done in 3 patients 
(1.6 %). Adjuvant chemotherapy was given in 93 patients 
(48.4%). 157 patients (81.8%) received systemic hormone 
therapy. The median age was 46 years (range, 25-73 years). 
182 patients (94.8%) were stage 0 to II and 10 patients (5.2%) 
with stage III breast cancer were also included. The boost 
dose delivered with electrons or tangential fields given in 
daily fractions of 1.5 to 2.5 Gy. The boost volume was 
described as the site of the primary tumor with a margin of 
1.5 cm to the field borders after breast conserving surgery. 
 
Results: The median follow-up duration for all patients was 
6.7 years. IBTR were considered as any local failures on 
ipsilateral breast regardless of the location. The 5-year 
cumulative risk of ipsilateral breast tumor recurrence as a 
first event was 5.4%. The 5-year local relapse free survival 
(LRFS) was 94.4%. IBTR occurred as a first failure in 13 of 192 
patients. In boost field recurrences were found in 11 patients 
(85%). 5 patients (39 %) were out-of boost field failures and 3 
of them were both failures. On univariate analysis, age, cell 
type, pT stage, pN stage, extensive intraductal component 
(EIC), multiplicity and location of resection margin were 
prognostic factor for IBTR (p <0.05). In multivariate analysis 
only young age (<40 years old) and positive radial resection 
margin were unfavorable prognostic factor for LRFS (p 
=0.037, p=0.021 respectively). pT stage was marginally 
significant prognostic factor for IBTR. (p=0.088) 
 
Conclusion: Median boost dose of 15 Gy is comparable to 
historical boost research results for local control in breast 
cancer patients with involved resection margin after BCT. 
Young age (<40 years old) and positive radial resection 
margin rather than superficial or deep margin were important 
risk factors for ipsilateral breast tumor recurrence. More than 
80% of local recurrences were in boost field, more boost dose 
escalation needs to be considered. 
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Purpose or Objective: Cancer-related fatigue is one of most 
prevalent symptom among women submitted to radiotherapy 
(RT) for breast cancer (BC). Despite its prevalence the 
mechanism of onset is unknown still: one possible mechanism 
is activation of the immune system, through the mediation by 
proinflammatory cytokines interleukin (IL), IL1-b,, IL-6, and 
tumor necrosis factor-a (TNF-a) as host response to tissue 
damage determined by the radiant treatment. To purpose of 
this study was to determine the level of fatigue in a group of 
BC patients its relation to anxiety, depression, serum 
cytokines, cortisol and blood count levels 
 
Material and Methods: Between October 2013 and May 2015 
twenty-eight patients who received adjuvant RT after breast 
conserving surgery were studied. The patients' subjective 
feeling of fatigue intensity was measured according to with 
two standardized self-assessment instruments the Fatigue 
Assessment Questionnaire (FAQ) and a visual analog scale 
(VAS) on fatigue intensity before the start and weekly during 
RT, as well as 14 days and 3-6 and 12 months after RT. In 
addition, a differential blood cell count and the serum levels 
of the cytokines- IL1-b,, IL-6, and TNF-a, were determined in 
parallel to the fatigue assessments. 
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Results: 60% of patients reported non presence of fatigue 
before the start of RT Fatigue intensity as assessed with the 
VAS increased gradually during radiotherapy, 14 days after 
the end of radiotherapy, the fatigue intensity was still higher 
than before treatment, but 3 months later, fatigue was lower 
than at the pre-treatment level. Fatigue measured with the 
FAQ did not increase significantly during treatment, but the 
subscores on physical and cognitive fatigue were elevated 
during treatment weeks 4 and 5. IL-1b, IL-6, and TNF-a, and 
hemoglobin levels did not change during therapy. Peripheral 
blood cell levels declined significantly during therapy and 
were still low 3 months after treatment. Until treatment 
week 5, lymphocytes were reduced to almost 50% of their 
initial values. Patients that introduce fatigue had 
significantly lower serum levels of cortisol than the 
nonfatigued patients as well as differences in two 
lymphocyte populations, at 3-6 and 12 months after the end 
of radiotherapy 
 
Conclusion: This study has shown that significant fatigue is 
common in patients receiving breast irradiation and is 
precipitated during radiotherapy in some patients but not 
other. In the patients that show an increase of the fatigue 
during adjuvant RT, fatigue returned to pre-treatment levels 
3 months after treatment. In our study, no evidence was 
found that anxiety, depression, serum levels of IL1-b, IL6, 
TNF-a and hemoglobin levels were correlate with treatment 
induced fatigue. The results of our observation suggest the 
existence of a mechanism among activation of the immune 
system and alteration in cortisol and lymphocyte subsets. 
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Purpose or Objective: There has been recent move within 
the U.K. to contour the nodal CTV for patients receiving 
adjuvant radiotherapy for breast cancer. Axillary 
radiotherapy (ART) following a positive sentinel lymph node 
biopsy is becoming more common for certain groups of 
patients. Organs at risk (OAR) should be delineated and 
considered during the planning process. Body mass index 
(BMI) has been shown to impact upon spinal cord and brachial 
plexus doses in irradiation of the supraclavicular fossa. The 
impact upon the OAR in the axilla has not yet been well 
documented.  
 
Material and Methods: Patients undergoing ART between 
01/04/15–01/10/15 were identified. Non - contrast 
radiotherapy planning CT scans were taken. External beam 
radiotherapy was planned with extended tangents using a 
field in field approach with an additional low weighted 
anterior oblique field if deemed appropriate for adequate 
dose coverage. Dose delivered was 40.05 Gy in 15 
fractions.BMI was calculated by: weight(kg)/height (m)2. 
CTV’s were contoured in accordance with the RTOG 
contouring atlas.OAR including ipsilateral lung, humeral head 
and brachial plexus were delineated. 
 
Results: Fifteen patients were identified. Six patients had a 
BMI between 20–25, 3 between 25–30, 5 between 30–40 and 1 
BMI>40. Mean ipsilateral lung V12 was 10.44% (range 2.3%–
14.33%). Mean V12 did not vary with BMI (BMI 20–25;mean 
V12=9.33%, BMI 25–30; mean V12=8.52%, BMI 30–40;mean 
V12=9.51%, BMI>40 mean V12=6.38%, p=0.55 Chi-Squared). 
The mean humeral head maximum dose was 35.2 Gy (range 
1.2–41.5 Gy). Mean humeral head maximum dose did not vary 
with BMI (BMI 20–25; mean=34.2Gy, BMI 25–30;mean=27.8Gy, 
BMI 30–40; mean=40.3Gy, BMI>40; mean=38.2Gy,p=0.49 t-
test). The ipsilateral brachial plexus D2 mean was15.6Gy 
(range 1.2–37.4 Gy). Mean ipsilateral brachial plexus D2 dose 
did not vary with BMI(p=0.21 t-test). 
 
Conclusion: BMI did not significantly impact upon OAR dosage 
although this series is limited by a small sample size. 
Ipsilateral lung and brachial plexus were comfortably within 
departmental tolerance. A planning risk volume of 10 mm 
around the humeral head has now been adopted within the 
department. It is recognised that intravenous contrast 
provides better quality images for delineating OAR in 
particular for the brachial plexus. However, this impacts 
upon resources in terms of radiographer scanning time. 
Adequate time needs to be allocated in consultant and 
physics teams job plans to enable high quality delineation 
and subsequent radiotherapy plans to be produced.  
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Purpose or Objective: Hypothyroidism is the most commonly 
reported long-term toxicity following radiotherapy to 
structures near to the thyroid gland. Emami suggested the 
thyroid gland tolerance as 45Gy (TD 5/5) although a much 
wider range of 10–80 Gy has been reported in the literature. 
When irradiating the supraclavicular fossa (SCF) in adjuvant 
radiotherapy for breast cancer, it is inevitable that the 
thyroid gland will receive a high dose of radiation due to its 
proximity to the target volume. Recently there has been a 
move to CT based delineation of the CTV and organs at risk 
(OAR) in patients requiring nodal radiotherapy for breast 
cancer compared with the previous bony land mark/field 
based techniques. Dose received by the thyroid gland and 
subsequent late toxicity has not yet been well studied in 
breast cancer. 
 
Material and Methods: Patients undergoing external beam 
radiotherapy to the breast or chest wall plus SCF between 
01/04/15–01/10/15 were identified. Radiotherapy planning 
contrast enhanced CT scans were taken. External beam 
radiotherapy was planned with tangents using a field in field 
approach with a matched direct anterior field. A low 
weighted posterior field was added if deemed appropriate for 
adequate dose coverage. Angle corrections were used as 
appropriate. A dose of 40.05 Gy in 15 fractions prescribed at 
depth was employed. CTV’s were contoured in accordance 
with the RTOG contouring atlas.The thyroid gland was 
prospectively delineated and D5% was recorded. 
 
Results: Seventeen patients undergoing adjuvant SCF 
radiotherapy were identified. T stage was as follows: T1:2 
patients,T2:9 patients,T3:4 patients, T4a:1 patient,T4d:1 
patient. N stage; N1:1 patient, N2:14 patients, N3:2 patients. 
Fourteen were hormone receptor positive, 3 hormone 
negative. Twelve were HER2 negative, 5 HER2 positive. Mean 
D5% thyroid was 37.9Gy (range 7–42.7 Gy). Excluding one 
patient with a previous hemi-thyroidectomy, the mean D5% 
thyroid was 39.8 Gy (range 16–42.7 Gy). An abnormality 
requiring referral to a surgeon for was discovered in one 
patient. 
 
Conclusion: Our departmental tolerance for the thyroid 
gland was set as 40Gy (for 2.67Gy per fraction). It is hard to 
achieve this without compromise of the CTV. The effect 
modern chemotherapy/targeted agents may have on this 
prior to receiving radiotherapy is inknown. Baseline TSH 
recording is desirable. Long-term follow up to detect clinical 
or biochemical thyroid dysfunction is needed to inform 
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